Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH-Reference-Cited by-同舟云学术

Everolimus selectively targets vemurafenib resistant BRAFV600E melanoma cells adapted to low pH

Published:2017-11 Issue: Volume:408 Page:43-54
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Ruzzolini Jessica,Peppicelli Silvia,Andreucci Elena,Bianchini Francesca,Margheri Francesca,Laurenzana Anna,Fibbi Gabriella,Pimpinelli Nicola,Calorini Lido

Funder

“Istituto Toscano Tumori”

“Ente Cassa di Risparmio Firenze”

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference39 articles.

1. Tumor adaptation and resistance to RAF inhibitors;Lito;Nat. Med.,2013

2. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma;Bollag;Nature,2010

3. BRIM-3 study group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N. Engl. J. Med.,2011

4. Inhibition of mutated, activated BRAF in metastatic melanoma;Flaherty;N. Engl. J. Med.,2010

5. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib;Sosman;N. Engl. J. Med.,2012

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The critical role of glutamine and fatty acids in the metabolic reprogramming of anoikis-resistant melanoma cells;Frontiers in Pharmacology;2024-08-08

2. Acidosis promotes the metastatic colonization of lung cancer via remodeling of the extracellular matrix and vasculogenic mimicry;International Journal of Oncology;2023-10-26

3. BRAF V600-Mutated Metastatic Melanoma and Targeted Therapy Resistance: An Update of the Current Knowledge;Cancers;2023-05-04

4. Extracellular Acidosis Differentially Regulates Estrogen Receptor β-Dependent EMT Reprogramming in Female and Male Melanoma Cells;International Journal of Molecular Sciences;2022-12-06

5. miR-214-Enriched Extracellular Vesicles Released by Acid-Adapted Melanoma Cells Promote Inflammatory Macrophage-Dependent Tumor Trans-Endothelial Migration;Cancers;2022-10-18